Scholarlink

Background <p>Epilepsy is a neurological syndrome caused by excessive neuronal discharges, with a part of the patients being pharmacoresistant to the traditional treatment.&#xa0;Cannabidiol, a non-psychoactive component of <i>Cannabis Sativa</i>, shows promise as an alternative, but further research is needed to quantify its efficacy.</p> Methods <p>This literature systematic review was made following the PRISMA protocol guidelines. The Google Scholar, Scielo, and PubMed/MEDLINE databases were included using the descriptors “Cannabidiol”, “Epilepsy”, and “Drug Resistant Epilepsy”. This research was registered in the Prospero platform with the identification (CRD42024479643).</p> Results <p>A total of 1448&#xa0;results were identified from&#xa0;the PubMed, Virtual Health Library, and Google Scholar databases. After applying exclusion criteria, six studies met the criteria for full-text evaluation and eligibility. The&#xa0;compiled analysis showed that the patients who received cannabidiol experienced a 41.0875% reduction in the total number of seizures,&#xa0;compared to an average reduction of 18.1%&#xa0;in placebo groups. This represents&#xa0;a 127% higher response rate&#xa0;for patients who received the intervention.</p> Conclusions <p>Given these results, it is possible to conclude that the therapeutic response of cannabidiol is worthy of consideration in new protocols and of being added to public healthcare systems for its antiepileptic potential. However, the high efficacy rate observed in the placebo group suggests that other methods of data collection analysis may be employed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The efficacy of cannabidiol for seizures reduction in pharmacoresistant epilepsy: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月17日

查看全文
  • Vinícius Gabino de Oliveira,
  • Natália Brito de Almeida,
  • Guilherme Corrêa Radmann,
  • Bruno Fernandes de Oliveira Santos

摘要

Background

Epilepsy is a neurological syndrome caused by excessive neuronal discharges, with a part of the patients being pharmacoresistant to the traditional treatment. Cannabidiol, a non-psychoactive component of Cannabis Sativa, shows promise as an alternative, but further research is needed to quantify its efficacy.

Methods

This literature systematic review was made following the PRISMA protocol guidelines. The Google Scholar, Scielo, and PubMed/MEDLINE databases were included using the descriptors “Cannabidiol”, “Epilepsy”, and “Drug Resistant Epilepsy”. This research was registered in the Prospero platform with the identification (CRD42024479643).

Results

A total of 1448 results were identified from the PubMed, Virtual Health Library, and Google Scholar databases. After applying exclusion criteria, six studies met the criteria for full-text evaluation and eligibility. The compiled analysis showed that the patients who received cannabidiol experienced a 41.0875% reduction in the total number of seizures, compared to an average reduction of 18.1% in placebo groups. This represents a 127% higher response rate for patients who received the intervention.

Conclusions

Given these results, it is possible to conclude that the therapeutic response of cannabidiol is worthy of consideration in new protocols and of being added to public healthcare systems for its antiepileptic potential. However, the high efficacy rate observed in the placebo group suggests that other methods of data collection analysis may be employed.